But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...
Philadelphia dad Eric Brunner was diagnosed with amyotrophic lateral sclerosis, the fatal disease known as ALS. He wants to ...
PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...
PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...
Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...
Live Science on MSN1d
'Exercise juice' released by muscles helps nerves grow, study findsIn a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...
There are now at least two patients who have had Neuralink's brain chip implanted in their head. While there have been some ...
The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...
A biotech start-up that has shown the ability to pause and in some cases reverse neurodegenerative diseases in mice has ...
A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback